Immunotherapy before and after surgery for head and neck cancer
Part of Cancer clinical trials.
This trial tests whether giving an immunotherapy drug called sintilimab before and after surgery can help treat head and neck cancer. The drug aims to boost your immune system to fight the cancer, and the goal is to improve outcomes when combined with the standard surgical treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of head and neck cancer (like mouth, throat, voice box) that can be removed with surgery.
- Your cancer must be stage III or IVA, meaning it is locally advanced but hasn't spread to distant parts of the body.
- You must not have had any cancer treatment yet (including surgery, radiation, chemo, or immunotherapy).
- You need to be in generally good health, with a performance status of 0 or 1 (meaning you are up and about).
- You must have normal organ function (liver, kidneys, blood counts) and no severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether adding an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) as maintenance therapy after chemoradiotherapy improves outcomes for people with locally advanced head and neck cancer. It specifically looks at a marker in your blood (CD8Tex cells) to see if you might benefit.
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests giving a combination of immunotherapy and chemotherapy before surgery, then immunotherapy afterwards, for head and neck cancer that has reached the skull base. The goal is to see if this approach can shrink the tumor and help improve long-term outcomes.
Hear when a new Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.